2024 EULAR Points to consider when treating patients with cancer
2024 EULAR Points to consider when using targeted therapies in patients with inflammatory arthritis and a history of cancer
Daily Download
My Cancelled Lecture Slides
Dr. Jack Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture.
JAKi Regulatory Decisions - FDA, EMA, Canada
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).
